Difference between revisions of "Talk:Case 52"
Jump to navigation
Jump to search
(? broader range of IHC for this case) |
(changes made) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
The list of IHC for which Dr Torres asks why includes the following choices that I think are reasonable | The list of IHC for which" Dr Torres asks why" includes the following choices that I think are reasonable | ||
CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and... | *CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and... | ||
Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids | *Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids | ||
PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable | *PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable | ||
::[https://librepathology.org/w/index.php?title=Case_52&diff=47416&oldid=29649 Changes were made] to the case as result of the comments. [[User:Michael|Michael]] ([[User talk:Michael|talk]]) 12:10, 23 May 2017 (EDT) | |||
Latest revision as of 16:11, 23 May 2017
The list of IHC for which" Dr Torres asks why" includes the following choices that I think are reasonable
- CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and...
- Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids
- PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable
- Changes were made to the case as result of the comments. Michael (talk) 12:10, 23 May 2017 (EDT)